Patient Perception of Dyskinesia in Parkinson's Disease
Overview
Neurosurgery
Psychiatry
Authors
Affiliations
Objective: To evaluate the perception of patients with Parkinson's disease (PD) regarding dyskinesia.
Design: Multicentre survey.
Setting: Tertiary referral centres.
Patients: Patients with PD participated in a survey: those not on dopaminergic medications (group I), those on dopaminergic medications without dyskinesia (group II) and those on dopaminergic medications with dyskinesia (group III).
Intervention: After a short standardised description and explanation of dyskinesia was provided, patients were asked about the nature and source of prior knowledge of dyskinesia. They were then asked about their perceptions of dyskinesia. Patients in group III were also asked about the duration, the severity of dyskinesia and whether their perception of this problem had changed since its appearance.
Main Outcome Measures: Level of concern regarding dyskinesia and whether their perception of dyskinesia would have changed their preference of treatment. Results 259 PD patients completed the survey (group I, 52; group II, 102; group III, 105). Patients with dyskinesia were significantly less concerned about dyskinesia than patients without dyskinesia and were more likely to choose dyskinesia over being parkinsonian. Patients who required fewer changes in medications because of dyskinesia were more likely to choose dyskinesia over parkinsonism.
Conclusion: Patients with PD experiencing dyskinesia are less likely to be concerned about dyskinesia and more likely to prefer dyskinesia over parkinsonian symptoms than patients without dyskinesia.
[Inhaled levodopa: from evidence to experience].
Martinez-Castrillo J, Parees-Moreno I, Lopez Sendon-Moreno J, Perez-Torre P, Fanjul S, Patino-Paton A Rev Neurol. 2024; 78(S01):S1-S10.
PMID: 38916176 PMC: 11513514. DOI: 10.33588/rn.78S01.2024196.
Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson's Disease.
Martinez-Nunez A, LeWitt P J Parkinsons Dis. 2023; 13(4):441-451.
PMID: 37182902 PMC: 10357202. DOI: 10.3233/JPD-230055.
Ravichandran V, Sadhu S, Convey D, Guerrier S, Chomal S, Dupre A Sensors (Basel). 2023; 23(6).
PMID: 36991587 PMC: 10054833. DOI: 10.3390/s23062877.
Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
Regensburger M, Ip C, Kohl Z, Schrader C, Urban P, Kassubek J J Neural Transm (Vienna). 2023; 130(6):847-861.
PMID: 36964457 PMC: 10199833. DOI: 10.1007/s00702-023-02623-8.
Defining the unknowns for cell therapies in Parkinson's disease.
Lane E, Lelos M Dis Model Mech. 2022; 15(10).
PMID: 36165848 PMC: 9555765. DOI: 10.1242/dmm.049543.